# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND OF THE INVENTION

- describe myositis and its treatment

## SUMMARY OF THE INVENTION

- introduce Insl6 protein for autoimmune disease treatment
- describe Insl6 protein conjugation to fusion partner
- summarize Insl6 protein's protective effect on muscle dysfunction
- describe Insl6 protein's regulation of T-regulatory cells
- outline method of using Insl6 gene product for autoimmune disease treatment
- specify autoimmune diseases that can be treated with Insl6
- describe method for treating autoimmune disease with Insl6 composition
- outline method for identifying subjects with muscle inflammatory disease
- describe Insl6 protein's reduction of inflammatory proteins
- outline administration routes for Insl6 composition

## DETAILED DESCRIPTION OF THE INVENTION

- introduce Insl6 protein and its variants
- describe therapeutic applications of Insl6
- detail methods of treating autoimmune diseases
- outline pharmaceutical compositions and administration

### DEFINITIONS

- define insulin-like 6
- define wild type
- define soluble Insl6 polypeptide
- define polynucleotide encoding Insl6
- define human Fc
- define polynucleotide encoding human Fc
- define mutant
- define muscle
- define autoimmune disease
- define immunosuppressive agents
- define inflammatory disorders
- define cytokine
- define chemokine
- define agent or compound
- define nucleic acid
- define gene
- define gene product
- define polypeptide or protein
- define modifications to polypeptides
- define peptide
- discuss use of non-natural amino acids
- define retro-inverso peptides
- describe synthesis of retro-inverso peptide analogues
- define fragment of a peptide
- describe functional fragments of Insl6
- define derivative of a peptide
- describe functional derivatives of Insl6
- define functional fragment of Insl6
- describe assessment of functional fragments
- define non-functional fragment of Insl6
- describe functional derivatives and mimetics
- define analog of Insl6
- describe chemical derivatives of Insl6
- define variant of Insl6 protein
- describe conservative and non-conservative amino acid substitutions
- describe variants of Insl6 polypeptide
- describe naturally-occurring, synthetic, recombinant, or chemically modified polynucleotides or polypeptides
- define conservative substitution
- provide examples of conservative substitutions
- describe selection of conservative amino acid substitutions
- define homology, identity, and similarity
- explain calculation of sequence identity
- define substantial identity
- define homologous and homologues
- describe substantially homologous sequences
- define substantially similar molecules
- explain substantially similar polynucleotide sequences
- describe substantially similar proteins
- define human homolog to a gene transcript
- define human homolog to a protein
- define conservative substitution
- define nonconservative substitution
- describe sequence comparison
- introduce PILEUP algorithm
- introduce BLAST algorithm
- describe statistical analysis of similarity
- define insertions and deletions
- define substitution
- define analog
- define covalently bonded
- define fusion protein
- define specifically binds
- define substantially pure
- define enhanced proteolytic stability
- define recombinant
- define subject, individual, tissue, disease, and composition
- define therapeutically effective amount
- define prophylactically effective amount
- define prevent, preventing, and prevention
- define administering and introducing
- define parenteral administration
- define systemic administration
- define pharmaceutically acceptable
- define pharmaceutically acceptable carrier
- define regeneration
- define vectors
- define viral vectors
- define promoter
- define regulatory sequences
- define operatively linked
- define biological sample
- define reduced, reduce, and decrease
- define low
- define increased, increase
- define high
- define articles a and an
- define about
- provide disclaimer for examples
- provide disclaimer for terminology

### Insulin-Like 6 (Insl6) Agents

- define Insl6 protein
- describe Insl6 gene segments
- discuss Insl6 protein processing
- introduce Insl6 polypeptide variants
- describe Insl6 protein functional fragments
- discuss Insl6 protein derivatives
- introduce modified RNA encoding Insl6
- describe Insl6 protein homologues
- discuss Insl6 protein similarity
- introduce Insl6 protein expression methods
- describe Insl6 protein production methods
- discuss Insl6 protein introduction into cells
- introduce cleavable peptides
- describe enzyme-cleavable peptides
- discuss Insl6 protein post-translational modification
- introduce Insl6 protein delivery methods
- describe Insl6 protein administration routes

### Insl6-Fc Fusion Proteins

- introduce Insl6 protein fusion partners
- describe Fc protein as a fusion partner
- list additional fusion partners and their functions
- motivate modifications to Insl6 proteins for increased half-life
- describe PEGylation as a modification approach
- discuss advantages and limitations of PEGylation
- introduce conjugation with long-lived proteins as an alternative approach
- describe albumin as a long-lived protein for conjugation
- discuss glycosylation as another approach to increase half-life
- introduce Fc fusion approach and its applications
- define conjugation and its various methods
- define Insl6-Fc fusion proteins
- conjugation methods
- linkers for conjugation
- targeting ligands
- muscle targeting
- cadherin domains as targeting ligands
- antibodies as targeting ligands
- immunoglobulin structure
- antibody fragments
- methods for preparing antibodies
- screening and selection of antibodies
- Insl6 agents
- modified RNA (mod-RNA) encoding Insl6 protein
- RNA activator (RNAa) for Insl6 gene expression
- small molecule activators of Insl6 expression

### Methods to Treat Autoimmune Diseases and Immune-Related Diseases and Disorders

- introduce autoimmune diseases and immune-related disorders
- describe treatment methods using Insl6 protein or agent
- detail pharmaceutical compositions comprising Insl6 protein or nucleic acid
- outline reduction of immune cells and pro-inflammatory cytokines
- specify decrease in immune cells and cytokines by percentage
- list pro-inflammatory cytokines
- describe treatment of inflammatory diseases or disorders
- detail treatment of sepsis
- outline treatment of other inflammatory conditions
- describe reduction of immune cells and cytokines in comparison to positive control
- introduce regulatory T cells and their role in immune system
- describe modification of regulatory T cell activity using Insl6 agent
- outline treatment of autoimmune diseases using compositions and methods
- list examples of autoimmune diseases
- describe treatment of autoimmune diseases with abnormal T-regulatory cell levels
- describe treatment of autoimmune diseases with high auto-immune antibody levels
- outline treatment of organ transplantation rejection or graft-vs-host-disease
- list autoimmune diseases
- list autoimmune diseases (continued)
- introduce Insl6 proteins and agents
- describe treatment of immune dysregulation diseases
- list specific autoimmune diseases treatable with Insl6 agents
- describe vascular disorders treatable with Insl6 agents
- list specific vascular disorders treatable with Insl6 agents
- describe symptoms of autoimmune diseases
- list diagnostic tests for autoimmune diseases
- describe treatment of conditions resulting from Insl6 deficiency
- describe treatment of subjects with high Insl6 levels
- describe subjects amenable to treatment with Insl6 agents
- describe diagnosis of myositis using Insl6 levels
- describe method of identifying individuals suitable for Insl6 treatment
- describe method of determining prognosis and diagnosis of myositis
- define reference level of Insl6 expression
- describe method of determining relative level of Insl6 in a subject
- describe quantitative detection of Insl6 protein/polypeptide
- describe automated immunohistochemistry systems
- describe automated protein expression analysis systems
- describe Insl6 gene expression level

### Administration of Pharmaceutical Compositions

- define administration routes
- describe dosage regimens
- motivate therapeutic effective dose
- summarize dosing frequency
- explain dosage adjustment
- describe effective amounts
- motivate LD50 and ED50
- explain therapeutic index
- describe animal model testing
- summarize dosage estimation
- describe pharmaceutical composition formulation
- motivate routes of administration
- describe local administration
- explain oral and parenteral administration
- summarize dosage unit forms

### Pharmaceutical Compositions

- formulate Insl6 agent in sterile injectable solution
- describe pharmacological formulation with compatible carrier
- list examples of delivery systems
- maintain proper fluidity with coating or surfactants
- add additives for stability, sterility, and isotonicity
- prevent microbial action with antibacterial and antifungal agents
- use isotonic agents for prolonged absorption
- describe lipid-based formulations
- list examples of lipids for synthetic membrane vesicle production
- consider variables for lipid-based vesicle preparation
- deliver Insl6 polypeptide in vesicle or controlled release system
- sterilize composition by gamma radiation or electron beam
- administer composition with other therapeutic agents
- formulate composition as pharmaceutical composition
- describe various forms of compositions
- prepare formulations by various means
- list inert diluents
- list adjuvants
- describe suspensions
- describe rectal or vaginal administration
- describe topical or transdermal administration
- describe ointments, pastes, creams, and gels
- describe powders and sprays
- describe transdermal patches
- describe parenteral administration
- describe aqueous and nonaqueous carriers
- describe adjuvants for parenteral administration
- describe injectable depot forms
- describe purification methods
- describe pharmaceutically acceptable salts, esters, amides, and prodrugs

### Gene Therapy

- introduce gene therapy
- administer insl6 agent as vector
- facilitate entry into cell
- provide polynucleotide with promoter
- use expression vectors compatible with eukaryotic cells
- describe viral vector systems
- direct expression in tissue- or cell-specific manner
- use constitutively active promoter
- use inducible promoter
- describe retroviral vector
- produce recombinant retroviral vector
- introduce vector DNA into packaging cell line
- describe adenovirus vectors
- use adenovirus vectors for gene therapy
- describe lentiviral vectors
- describe adeno-associated virus vectors
- transfer gene to cells in tissue culture
- introduce gene into target cell
- describe methods for delivering DNA-cationic lipid complexes
- introduce human Insl6 protein or Insl6-Fc fusion polypeptide
- administer pharmaceutical compositions

### Kits

- provide kits or pharmaceutical packages
- include Insl6 agent composition
- specify forms of composition
- optionally include instructions
- optionally include other pharmaceutically active agents
- optionally include materials for administration
- define permutations of elements
- introduce numbered paragraphs
- describe methods for treating autoimmune diseases
- specify autoimmune diseases
- describe methods for treating myositis
- describe methods for treating T-cell mediated autoimmune diseases
- describe fusion proteins
- provide pharmaceutical compositions and methods

## EXAMPLES

- provide illustrative examples

### Example 1

- describe CIM model establishment
- evaluate Insl6 overexpressing mice
- analyze inflammation reduction

